ACVRL1 and neoplasm: We and others have previously exploited targeting of ALK1 activity to impinge on tumor growth, either through genetic or pharmacological means (9–11), e.g., via the ligand trap RAP-041/dalantercept (referred to as ALK1-Fc from hereon).